Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,512.38 -3.89 -0.03%
TOPIX 1,171.40 -1.97 -0.17%
HANG SENG 22,760.24 64.23 0.28%

Supernus Appoints Victor Vaughn as Senior Vice President of Sales



Supernus Appoints Victor Vaughn as Senior Vice President of Sales

ROCKVILLE, Md., Jan. 14, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals,
Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced the
appointment of Victor Vaughn to the position of Senior Vice President of
Sales. Mr. Vaughn will be responsible for leading all of the company's sales
activities.

"Victor has an outstanding track record of success in building sales
organizations and launching specialty products specifically in the epilepsy
and ADHD areas. He led the Shire sales organization for 13 years with sales
reaching more than $1 billion behind products including Carbatrol^® in
epilepsy and Adderall XR^® in ADHD," said Jack Khattar, president and CEO of
Supernus. "Victor has been working with us for more than three years in a
consulting capacity helping to build our sales organization and to prepare for
the launches of Oxtellar XR™ and Trokendi XR™. We are very excited to have him
join us on a full time basis as a member of our executive team. Victor's
significant experience in executing one of the most successful immediate
release (IR) to extended release (XR) switches in our industry will be pivotal
to our execution on the upcoming launches of our two epilepsy XR products."

Mr. Vaughn has over 30 years of experience in the pharmaceutical industry. For
the past seven years he has been consulting with small to medium size
pharmaceutical companies, assisting them with their commercial operations.
From 1992 to 2005, he led the sales organization at Shire where he last served
as senior vice president of sales. Prior to that, he held various positions in
sales and sales management at Fujisawa and SmithKline Beecham (Glaxo). Mr.
Vaughn earned his bachelor degree in business administration from East
Tennessee State University.

"I am excited to be joining the Supernus team and working on launching two
important products in epilepsy," said Victor Vaughn, senior vice president of
sales. " I am very much looking forward to being part of the great growth
opportunity that lies ahead for Supernus and to the chance to positively
affect the lives of patients suffering from epilepsy, ADHD and other CNS
disorders."

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on developing and commercializing products for the treatment of central
nervous system, or CNS, diseases. The Company has one approved product for
epilepsy, Oxtellar XR™ (extended-release oxcarbazepine), and one tentatively
approved product for epilepsy, Trokendi XR™ (extended-release topiramate). The
Company is also developing several product candidates in psychiatry to address
large market opportunities in ADHD, including ADHD patients with impulsive
aggression. These product candidates include SPN-810 for impulsive aggression
in ADHD and SPN-812 for ADHD.

Forward-Looking Statements:

This press release includes forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. These statements do not
convey historical information, but relate to predicted or potential future
events that are based upon management's current expectations. These statements
are subject to risks and uncertainties that could cause actual results to
differ materially from those expressed or implied by such statements. In
addition to the factors mentioned in this press release, such risks and
uncertainties include, but are not limited to, the Company's ability to raise
sufficient capital to implement its corporate strategy; the implementation of
the Company's corporate strategy; the Company's future financial performance
and projected expenditures; the Company's product research and development
activities, including the timing and progress of the Company's clinical
trials, and projected expenditures; the Company's ability to receive, and the
timing of any receipt of, regulatory approvals to develop and commercialize
the Company's product candidates; the Company's ability to protect its
intellectual property and operate its business without infringing upon the
intellectual property rights of others; the Company's expectations regarding
federal, state and foreign regulatory requirements; the therapeutic benefits,
effectiveness and safety of the Company's products and product candidates; the
accuracy of the Company's estimates of the size and characteristics of the
markets that may be addressed by its products and product candidates; the
Company's ability to increase its manufacturing capabilities for its products
and product candidates; the Company's projected markets and growth in markets;
the Company's staffing needs; and other risk factors set forth from time to
time in the Company's periodic reports and other filings made with the
Securities and Exchange Commission. The Company undertakes no obligation to
update the information in this press release to reflect events or
circumstances after the date hereof or to reflect the occurrence of
anticipated or unanticipated events.

Carbatrol^® and Adderall XR^® are registered trademarks of Shire LLC

CONTACT: Jack Khattar, President & CEO
         Gregory S. Patrick, Vice President and CFO
         Supernus Pharmaceuticals, Inc.
         Tel: (301) 838-2591
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement